Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 17/20 | 0.67 |
| ▸ | ESR1 | P03372 | 17/20 | 0.67 |
| ▸ | PTGES | O14684 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22310460 | 1.00 | ESR2 (0.67) | ESR2ESR1PTGESALOX5 | |
| SCHEMBL3583554 | 1.00 | ESR2 (0.67) | ESR2ESR1PTGESALOX5 | |
| SCHEMBL30357059 | 1.00 | ESR2 (0.67) | ESR2ESR1PTGESALOX5 | |
| SCHEMBL30357024 | 1.00 | ESR2 (0.67) | ESR2ESR1PTGESALOX5 | |
| Erteberel SCHEMBL14534968 | 0.80 | ESR2 (1.00) | ESR2ESR1 | |
| Erteberel SCHEMBL14102412 | 0.80 | ESR2 (1.00) | ESR2ESR1 | |
| Erteberel SCHEMBL14514726 | 0.80 | ESR2 (1.00) | ESR2ESR1 | |
| Erteberel SCHEMBL14102383 | 0.80 | ESR2 (1.00) | ESR2ESR1 | |
| Erteberel SCHEMBL14514704 | 0.80 | ESR2 (1.00) | ESR2ESR1 | |
| SCHEMBL14047367 | 0.80 | ESR2 (1.00) | ESR2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298925-A1 | SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | DURST GREGORY LEE | 2009-12-03 | — | — | US | claimed |
| US-20080312312-A1 | SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | DURST GREGORY LEE | 2008-12-18 | — | — | US | claimed |
| EP-1626974-B1 | SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | LILLY CO ELI (US) | 2008-08-27 | — | — | EP | claimed |
| US-7842822-B2 | Substituted benzopyrans as selective estrogen receptor-beta agonists | ELI LILLY AND COMPANY (US) | 2010-11-30 | — | — | US | disclosed |
| US-20090298925-A1 | SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | DURST GREGORY LEE | 2009-12-03 | — | — | US | disclosed |
| US-7585985-B2 | Substituted benzopyrans as selective estrogen receptor-beta agonists | ELI LILLY AND COMPANY (US) | 2009-09-08 | — | — | US | disclosed |
| US-20080312312-A1 | SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | DURST GREGORY LEE | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298925-A1 | SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | GPER1, ESR2, ESR1 | ESR2 2/4885ESR1 3/4885PTGES 214/4885 |
| US-20080312312-A1 | SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | GPER1, ESR2, ESR1 | ESR2 2/4885ESR1 3/4885PTGES 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.